These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 9797203)

  • 1. Resistance to human immunodeficiency virus type 1 protease inhibitors.
    Boden D; Markowitz M
    Antimicrob Agents Chemother; 1998 Nov; 42(11):2775-83. PubMed ID: 9797203
    [No Abstract]   [Full Text] [Related]  

  • 2. [Resistance to protease inhibitors].
    Clotet B; Martínez-Picado J; Arrizabalaga J; Ruiz L
    Enferm Infecc Microbiol Clin; 2001 Feb; 19(Monografico):34-41. PubMed ID: 11428058
    [No Abstract]   [Full Text] [Related]  

  • 3. Long-term effects of HIV-1 protease inhibitors on insulin secretion and insulin signaling in INS-1 beta cells.
    Schütt M; Zhou J; Meier M; Klein HH
    J Endocrinol; 2004 Dec; 183(3):445-54. PubMed ID: 15590971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The utility of inhibitory quotients in determining the relative potency of protease inhibitors.
    Piliero PJ
    AIDS; 2002 Mar; 16(5):799-800. PubMed ID: 11964541
    [No Abstract]   [Full Text] [Related]  

  • 5. Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro.
    Granfors MT; Wang JS; Kajosaari LI; Laitila J; Neuvonen PJ; Backman JT
    Basic Clin Pharmacol Toxicol; 2006 Jan; 98(1):79-85. PubMed ID: 16433896
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of P-glycoprotein expression by HIV protease inhibitors in cell culture.
    Perloff MD; von Moltke LL; Fahey JM; Daily JP; Greenblatt DJ
    AIDS; 2000 Jun; 14(9):1287-9. PubMed ID: 10894301
    [No Abstract]   [Full Text] [Related]  

  • 7. HIV protease inhibitors.
    Carr A; Cooper DA
    AIDS; 1996; 10 Suppl A():S151-7. PubMed ID: 8883623
    [No Abstract]   [Full Text] [Related]  

  • 8. Natural polymorphisms in the human immunodeficiency virus type 2 protease can accelerate time to development of resistance to protease inhibitors.
    Ntemgwa M; Brenner BG; Oliveira M; Moisi D; Wainberg MA
    Antimicrob Agents Chemother; 2007 Feb; 51(2):604-10. PubMed ID: 17116674
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV-1 protease mutations and protease inhibitor cross-resistance.
    Rhee SY; Taylor J; Fessel WJ; Kaufman D; Towner W; Troia P; Ruane P; Hellinger J; Shirvani V; Zolopa A; Shafer RW
    Antimicrob Agents Chemother; 2010 Oct; 54(10):4253-61. PubMed ID: 20660676
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of coadministration of nelfinavir, indinavir, and saquinavir on the pharmacokinetics of amprenavir.
    Pfister M; Labbé L; Lu JF; Hammer SM; Mellors J; Bennett KK; Rosenkranz S; Sheiner LB;
    Clin Pharmacol Ther; 2002 Aug; 72(2):133-41. PubMed ID: 12189360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification and structural characterization of I84C and I84A mutations that are associated with high-level resistance to human immunodeficiency virus protease inhibitors and impair viral replication.
    Mo H; Parkin N; Stewart KD; Lu L; Dekhtyar T; Kempf DJ; Molla A
    Antimicrob Agents Chemother; 2007 Feb; 51(2):732-5. PubMed ID: 17101675
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The influence of protease inhibitor resistance profiles on selection of HIV therapy in treatment-naive patients.
    Turner D; Schapiro JM; Brenner BG; Wainberg MA
    Antivir Ther; 2004 Jun; 9(3):301-14. PubMed ID: 15259893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical pharmacology of HIV protease inhibitors: focus on saquinavir, indinavir, and ritonavir.
    Hoetelmans RM; Meenhorst PL; Mulder JW; Burger DM; Koks CH; Beijnen JH
    Pharm World Sci; 1997 Aug; 19(4):159-75. PubMed ID: 9297727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV protease inhibitors are inhibitors but not substrates of the human breast cancer resistance protein (BCRP/ABCG2).
    Gupta A; Zhang Y; Unadkat JD; Mao Q
    J Pharmacol Exp Ther; 2004 Jul; 310(1):334-41. PubMed ID: 15007102
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Select HIV protease inhibitors alter bone and fat metabolism ex vivo.
    Jain RG; Lenhard JM
    J Biol Chem; 2002 May; 277(22):19247-50. PubMed ID: 11937496
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of HIV protease inhibitors on barrier function in the human intestinal cell line HT-29/B6.
    Bode H; Schmidt W; Schulzke JD; Fromm M; Riecken EO; Ullrich R
    Ann N Y Acad Sci; 2000; 915():117-22. PubMed ID: 11193566
    [No Abstract]   [Full Text] [Related]  

  • 17. Peptidomimetic inhibitors of HIV protease.
    Randolph JT; DeGoey DA
    Curr Top Med Chem; 2004; 4(10):1079-95. PubMed ID: 15193140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro susceptibility and virological outcome to darunavir and lopinavir are independent of HIV type-1 subtype in treatment-naive patients.
    Dierynck I; De Meyer S; Lathouwers E; Vanden Abeele C; Van De Casteele T; Spinosa-Guzman S; de Béthune MP; Picchio G
    Antivir Ther; 2010; 15(8):1161-9. PubMed ID: 21149923
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protease sequences from HIV-1 group M subtypes A-H reveal distinct amino acid mutation patterns associated with protease resistance in protease inhibitor-naive individuals worldwide. HIV Variant Working Group.
    Pieniazek D; Rayfield M; Hu DJ; Nkengasong J; Wiktor SZ; Downing R; Biryahwaho B; Mastro T; Tanuri A; Soriano V; Lal R; Dondero T
    AIDS; 2000 Jul; 14(11):1489-95. PubMed ID: 10983635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential effect of HIV protease inhibitors on adipogenesis: intracellular ritonavir is not sufficient to inhibit differentiation.
    Vernochet C; Azoulay S; Duval D; Guedj R; Ailhaud G; Dani C
    AIDS; 2003 Oct; 17(15):2177-80. PubMed ID: 14523274
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.